Wolters Kluwer Drug Pricing

October 17th, 2018 - Find-A-Code

Categories: Drugs|Pharmaceuticals|FDA Audits/Auditing Practice Management Medicaid Medicare

Wolters Kluwer provides unit and package pricing for multiple drug price types: Average Wholesale Price (AWP), Wholesale Acquisition Cost (WAC), Direct Price (DP), Manufacturer's Suggested Wholesale Price (SWP), Centers for Medicare & Medicaid Services, Federal Upper Limit (CMS FUL), Average Average Wholesale Price (AAWP), Generic Equivalent Average Price (GEAP).

Average Wholesale Price (AWP)

In the United States, the average wholesale price (AWP) is a pharmaceutical term that describes the average price paid by a retailer to buy a drug from the wholesaler. The AWP may be determined by several different methods.

The drug manufacturer may report the AWP to the individual publisher of drug pricing data
The AWP may also be calculated by the publisher based upon a mark-up specified by the manufacturer that is applied to the wholesale acquisition cost (WAC) or direct price (DP).
The wholesale acquisition cost (WAC) is the manufacturer’s list price of the drug when sold to the wholesaler. Pharmacies typically buy their drugs from wholesalers. WAC is the most common benchmark used today by pharmacies to buy drugs from wholesalers.
Typically a 20% mark-up is applied to the manufacturer-supplied WAC or DP, which results in the AWP.

Wholesale Acquisition Cost (WAC)

The wholesale acquisition cost (WAC) is an estimate of the manufacturer's list price for a drug to wholesalers or direct purchasers. WAC does not always represent the sales price in a single transaction accurately, as the manufacturer can choose to offer discounts or rebates that lower the price of which the product is sold to the wholesaler.

Direct Price (DP)

Direct Price is the price at which non-wholesalers and providers can purchase drug products from a manufacturer. These prices can vary by transaction, as the manufacturer may offer discounts or rebates.

Manufacturer's Suggested Wholesale Price (SWP)

SWP is the reported price from the manufacturer for its drugs to be sold by wholesalers to customers. This does not reflect the pricing from the manufacturer to the customers. Wholesalers will determine the actual price of the product based on competitive and market factors.

Federal Upper Limit (CMS FUL)

The list of covered drug products comes directly from CMS and is updated periodically. They establish ceiling prices for each set of therapeutically equivalent drug products according to the formula in the Medicaid final regulation published July 31, 1987, by CMS' parent organization, the Department of Health and Human Services (HHS). The rule's reimbursement ceiling is set at 150% of the lowest published price for therapeutically equivalent drug products.

Average Wholesale Price (AAWP) & Generic Equivalent Average Price (GEAP)

The AAWP is a Wolters Kluwer Clinical Drug Information drug pricing concept. Generally, the AAWP represents the average of all AWPs for each multi-source drug product. The AAWP is not calculated when the number of manufacturers supplying a generic is insufficient.

The Generic Equivalent Average Price (GEAP) is a Wolters Kluwer Clinical Drug Information drug pricing concept. The GEAP is not calculated when the number of manufacturers supplying a generic is insufficient. The GEAP is a generic price applied to all drug products sharing the same GPPC; however, all drug products with the same GPPC have not been used in the determination of the GEAP.

To learn more, click here.

###

Questions, comments?

If you have questions or comments about this article please contact us. Comments that provide additional related information may be added here by our Editors.

Latest articles: (any category)

COVID Vaccine Coding Changes as of November 1, 2023
October 26th, 2023 - Wyn Staheli

COVID vaccine changes due to the end of the PHE as of November 1, 2023 are addressed in this article.

Medicare Guidance Changes for E/M Services
October 11th, 2023 - Wyn Staheli

2023 brought quite a few changes to Evaluation and management (E/M) services. The significant revisions as noted in the CPT codebook were welcome changes to bring other E/M services more in line with the changes that took place with Office or Other Outpatient Services a few years ago. As part of CMS’ Medicare Learning Network, the “Evaluation and Management Services Guide” publication was finally updated as of August 2023 to include the changes that took place in 2023. If you take a look at the new publication (see references below),....

Can We Score Interpretation of an EKG Towards E/M Medical Decision Making?
October 10th, 2023 - Aimee Wilcox

When EKGs are performed in the facility setting or even in the physician's office, what are the requirements for reporting the service and who gets credit for scoring data points for Evaluation and Management (E/M) medical decision making (MDM)? Let's take a look at a few coding scenarios related to EKG services to get a better understanding of why this can be problematic.

Accurately Reporting Signs and Symptoms with ICD-10-CM Codes
October 5th, 2023 - Aimee Wilcox

Coders often find themselves unsure of when to report a sign or symptom code documented in the medical record. Some coders find their organization has an EHR that requires a working diagnosis, which is usually a sign or symptom, be entered to order a test or diagnostic study or image. Understanding the guidelines surrounding when signs and symptoms should be reported is the first step in correct coding so let's take a look at some scenarios.

The 2024 ICD-10-CM Updates Include New Codes for Reporting Metabolic Disorders and Insulin Resistance
September 19th, 2023 - Aimee Wilcox

Diabetes is a chronic disease that just seems to consistently be increasing instead of improving resulting in a constant endeavor by medical researchers to identify causal effects and possible treatments. One underlying or precipitating condition that scientists have identified as a precipitating factor in the development of diabetes is insulin resistance, which is a known metabolic disorder. As data becomes available through claims reporting, additional code options become possible with ICD-10-CM.

Documenting and Reporting Postoperative Visits
September 12th, 2023 - Aimee Wilcox

Sometimes we receive questions regarding documentation requirements for specific codes or coding requirements and we respond with information and resources to support our answers. The following question was recently submitted: Are providers required to report postoperative services on claims using 99024, especially if there is no payment for that service? What documentation is required if you are reporting an unrelated Evaluation and Management (E/M) service by the same physician during the postoperative period?

Understanding Gastroesophageal Reflux Disease and ICD-10-CM Coding
August 22nd, 2023 - Aimee Wilcox

Gastroesophageal reflux disease or GERD for short, is a disease that impacts millions of Americans on a weekly basis. Symptoms are uncomfortable, as are some of the tests used to diagnose it, but understanding the disease, tests, and treatments helps us better understand how to code the disease using ICD-10-CM codes.